Waters expands mass spectrometry portfolio to fast-track drug development
Category: #tech  | By Mateen Dalal  | Date: 2022-06-07 |
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

Waters expands mass spectrometry portfolio to fast-track drug development

Waters Corporation has recently introduced new software, instruments and product enhancements to accelerate the drug discovery and development at the ASMS (American Society for Mass Spectrometry) 2022 Annual Conference.

The products under these innovations include the CONFIRM Sequence – an advanced oligonucleotide sequencing authorization app for the waters_connect™ software platform, a new Xevo™ G3 QTof (quadrupole time-of-flight) mass spectrometer, and an electrospray ionization basis for the multi spectral Waters™ SELECT SERIES™ (MRT Multi-Reflecting Time) of Flight mass spectrometer.

Jon Pratt, Senior Vice President at Waters Corporation, said that the innovations in mass spectrometry advance swiftly.

Jon added that the new product portfolio is anticipated to benefit scientists throughout the drug development cycle.

For researchers, this would mean boosting the capability for resolving fundamental scientific questions while for the analytical scientist accumulating analytical data to file a new drug, it means enlarged certainty and self-assurance in knowing exactly what is in the testers and in what quantities.

The novel Xevo G3 QTof system, amongst the many unveiled, is a sophisticated, benchtop mass spectrometer for quantifying and characterizing molecules in applications like forensics, biotherapeutics, metabolomics, metabolite identification, and leachables and extractables.

The product is 10 times more sensitive than its predecessor at transferring thermally fragile molecules and excels at characterizing and measuring native or denatured peptides, proteins, and other biotherapeutics.

Dr. Andrew Mahan, Mass Spectrometry Group Leader, Associate Director of Cell Engineering & Early Development, Janssen, said that the biopharmaceutical commercialization and development requires a deep understanding of product distinction, the degradation pathways, and procedures that make them.

It has been claimed that the protracted mass-to-charge ratio (m/z) series of the Xevo G3 QTof is expected to be idyllic for analyzing multi-specifics and instinctive MS analyses.

Waters developed the Xevo G3 QTof system to consistently offer scientists the reproducible and exact qualitative and quantitative information related to molecules in their samples, whether in very large or very small amounts.

Source Credit - https://www.socialnews.xyz/2022/06/06/waters-introduces-high-resolution-mass-spectrometry-products-and-software-to-accelerate-drug-development/

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal     twitter

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More..

More News By Mateen Dalal

Apollo plans to expand looking at average occupancy surge

Apollo plans to expand looking at average occupancy surge

By Mateen Dalal

Apollo Hospitals Enterprises Ltd., one of India's leading healthcare providers, is reportedly targeting to increase the average occupancy rate in its hospitals to 68-70% for the fiscal year 2024. The company recently announced impressive finan...

ChatGPT’s creator OpenAI proposes regulation of AI by humans

ChatGPT’s creator OpenAI proposes regulation of AI by humans

By Mateen Dalal

OpenAI, the creator of ChatGPT, has reportedly put forward a proposal for the establishment of an international organization to regulate artificial intelligence (AI). Led by CEO Sam Altman, the company believes that AI systems developed within the ne...

Medtronic pledges USD 350 Mn to expand R&D operations in India

Medtronic pledges USD 350 Mn to expand R&D operations in India

By Mateen Dalal

Medtronic, a leading healthcare technology company, has announced plans to expand its R&D center in Hyderabad, India, with a whopping investment of USD 350 million. The existing facility is already the largest center for the company outside the U...